홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

오베티콜산

Obeticholic Acid

HCID 447715
새 반응
인쇄

데이터를 보충하는 중입니다. 잠시 후 페이지를 새로 고치면 최신 내용을 볼 수 있습니다

기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
459789-99-2
표준 SMILES
CC[C@H]1[C@@H](O)[C@@H]2[C@H](CC[C@]3(C)[C@@H]([C@H](C)CCC(=O)O)CC[C@@H]23)[C@@]2(C)CC[C@@H](O)C[C@@H]12
InChIKey
ZXERDUOLZKYMJM-ZWECCWDJSA-N
분자식
C26H44O4
평균 분자량
420.6 g/mol
단동위원소 질량
420.32395988

개요

Obeticholic acid is a dihydroxy-5beta-cholanic acid that is chenodeoxycholic acid carrying an additional ethyl substituent at the 6alpha-position. A semi-synthetic bile acid which acts as a farnesoid X receptor agonist and is used for treatment of primary biliary cholangitis. It has a role as a farnesoid X receptor agonist and a hepatoprotective agent. It is a dihydroxy-5beta-cholanic acid, a 3alpha-hydroxy steroid and a 7alpha-hydroxy steroid. It is functionally related to a chenodeoxycholic acid.

이름 및 식별자

우선 이름
Obeticholic Acid
IUPAC
(4R)-4-[(3R,5S,6R,7R,8S,9S,10S,13R,14S,17R)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
현지명
오베티콜산
영어명
Obeticholic Acid
분자식
C26H44O4
분자량
420.63

이름 및 동의어

Obeticholic acid459789-99-26-ECDCAINT-7476-Ethylchenodeoxycholic acidOcaliva6-Ethyl-CDCAacido obeticolicoacide obeticholiqueDSP-1747INT747INT 747
이름 더 보기
오베티콜산Obeticolic acid(R)-4-((3R,5S,6R,7R,8S,9S,10S,13R,14S,17R)-6-ethyl-3,7-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid94701osv6alphC15636CS-1441
6alpha-ethylchenodeoxycholic acid6alpha-ethyl-3alpha,7alpha-dihydroxy-5beta-cholan-24-oic acid6-ethyl-3,7-dihydroxycholan-24-oic acidDSP17470462Z4S4OZCHEBI:43602DTXSID201966716-alpha-ethylchenodeoxycholic acid

데이터베이스 식별자

CAS
459789-99-2
PubChem CID
447715
DTXSID
DTXSID20196671
ChEMBL

물성

구조 계산 물성보충 중

XLogP
5.7
극성 표면적
77.8 Ų
수소 결합 공여자 수
3
수소 결합 수용자 수
4
회전 가능 결합 수
5
무거운 원자 수
30
형식 전하
0
복잡도
649

실험 및 물리화학적 성질

DrugsPharmaceuticals -> Listed in ZINC15
Human Drugs · 2건

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Boiling Point562.9±25
Melting Point108-110
Dissociation Constants4.76±0.10

물리화학적 성질

녹는점
108 · 108-110 °C
끓는 점
562.9 · 562.9±25.0 °C(Predicted)
밀도
1.091 · 1.091
저장 조건
-20 °C · -20°C
용해도
DMSO(최대 35mg/ml) 또는 에탄올(최대 25mg/ml)에 용해됩니다.
물리적 상태
백색 고체.
산도 계수 (pKa)
4.76 · 4.76±0.10(Predicted)
색상
하얀색
안정성
2 · 제공된 대로 구매일로부터 2년 동안 안정적입니다. DMSO 또는 에탄올 용액은 -20°C에서 최대 2개월 동안 보관할 수 있습니다.

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 4건

Warning

H315 (40%): Causes skin irritation [Warning Skin corrosion/irritation]

P203, P260, P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P318, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 5 reports by companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

유해성 정보

Hazard Classes and CategoriesSkin Irrit. 2 (40%)

독성 정보

Hepatotoxicity · 1건

In multiple preregistration clinical trials, obeticholic acid was found to decrease serum enzyme elevations in a high proportion of patients with different liver diseases. Instances of paradoxical worsening of liver disease or further increases in serum ALT or AST were not reported. However, the product label for obeticholic acid includes warnings that serious liver related adverse events occurred more commonly with active therapy than with placebo treatment. In a pooled analysis of 3 placebo controlled trials in patients with primary biliary cholangitis, liver related adverse events were 5.2 per 100 patient exposure years with 10 mg and 2.4 with placebo. Even higher rates occurred with higher doses of obeticholic acid: 19.8 per 100 patient years for 25 mg daily and 54.5 for 50 mg daily. The clinical features, timing of onset, pattern of enzyme elevations and course of these events were not described in detail. Within a little over a year after approval of obeticholic acid as therapy for primary biliary cholangitis, the FDA published a warning letter stating that they had received notification of 19 deaths and 11 cases of severe liver injury in patients taking obeticholic acid, most but not all of whom had preexisting cirrhosis (Case 1). More recently, severe instances of hepatic decompensation have been reported in patients with both primary biliary cholangitis as well as primary sclerosing cholangitis, two similar chronic cholestatic liver diseases.

화학 및 산업

약리 정보

ATC Code · 3건

A05AA04

A - Alimentary tract and metabolism

QA - Alimentary tract and metabolism

Protein BindingObeticholic acid and its metabolic conjugates are >99% plasma protein-bound.
Pharmacodynamics · 1건

The activation of the FXR by obeticholic acid acts to reduce the synthesis of bile acids, inflammation, and the resulting hepatic fibrosis. This may increase the survival of patients with PBC, but to date, an association between obeticholic acid and survival in PBC has not been established.

Mechanism of Action · 1건

Primary biliary cirrhosis is an autoimmune process by which the bile ducts and liver are damaged progressively, leading to fibrosis and cirrhosis. Bile acids increase the risk of damage and fibrosis to the damaged bile ducts. Obeticholic acid is a potent agonist of the farnesoid X receptor, which serves to regulate the hepatic metabolism of bile and cholesterol. This drug acts by binding to the farnesoid X receptor (FXR), found in the nucleus of liver and intestinal cells, which in turn increases liver bile flow, suppressing its production and decreasing hepatocyte exposure to excess levels of bile with cholestasis. Cholestasis is a process that normally causes inflammation and cirrhosis of the liver.

Biological Half-LifeThe biological half-life of obeticholic acid is reported to be 24 hours.
Metabolism/Metabolites · 1건

The metabolism of obeticholic acid occurs in the liver. Obeticholic acid is conjugated with glycine or taurine, followed by secretion into bile. The conjugates are then absorbed in the small intestine and then re-enter the liver via enterohepatic circulation. The intestinal microbiota in the ileum converts conjugated obeticholic acid in a deconjugated form that may be either reabsorbed or eliminated. Glycine conjugates account for 13.8% of the metabolites and taurine conjugates account for 12.3%. Another metabolite, 3-glucuronide, may also be formed, but displays little pharmacological activity.

관련 반응

19건
반응 기록 만들기
HRID 591866 반응식
HRID 591866반응물로
HRID 591867 반응식
HRID 591867반응물로
HRID 591868 반응식
HRID 591868반응물로
HRID 591869 반응식
HRID 591869반응물로
HRID 591870 반응식
HRID 591870반응물로
HRID 591871 반응식
HRID 591871반응물로
HRID 591872 반응식
HRID 591872생성물로
HRID 591874 반응식
HRID 591874생성물로
이전1 / 3 페이지

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
CHEMBL566315
ChEBI
CHEBI:43602
UNII
0462Z4S4OZ
EC Number
810-245-2
Nikkaji
J2.007.345D
InChIKey
ZXERDUOLZKYMJM-IMGBAYNYNA-N
SMILES
C[C@]12CC[C@@H](O)C[C@@]1([H])[C@@H](CC)[C@@H](O)[C@@]1([H])[C@]3([H])CC[C@]([H])([C@H](C)CCC(=O)O)[C@@]3(C)CC[C@]21[H] |&1:1,4,7,9,12,14,16,20,22,29,33,r|
Adverse Effects · 1건

The most common adverse effects associated with OCA administration include pruritus, fatigue, and abdominal pain and discomfort. Other reported adverse effects include rash, oropharyngeal pain, dizziness, constipation, arthralgia, dyslipidemia, headache, eczema, depression, hypersensitivity reactions, and abnormal thyroid function. The incidence of pruritus has been shown to increase in a dose-dependent manner and is increased when OCA is used as monotherapy. However, if a patient undergoes OCA therapy for 3 months without pruritus, this adverse effect is unlikely to occur subsequently.

Toxicity SummarySigns and Symptoms of Overdose
Drug Induced Liver Injury · 6건

Drug Induced Liver Injury Rank (DILIrank 2.0)

Obeticholic acid

vMost-DILI-concern

8

Box warning

DOI:10.1016/j.drudis.2016.02.015

안전 데이터

wgk
WGK 3
HS 번호
2918199890
스토리지 클래스
11 - Combustible Solids
FDA Pharmacological Classification · 5건

0462Z4S4OZ

OBETICHOLIC ACID

Established Pharmacologic Class [EPC] - Farnesoid X Receptor Agonist

Mechanisms of Action [MoA] - Farnesoid X Receptor Agonists

Obeticholic acid is a Farnesoid X Receptor Agonist. The mechanism of action of obeticholic acid is as a Farnesoid X Receptor Agonist.

Absorption, Distribution and Excretion · 4건

Obeticholic acid is absorbed in the gastrointestinal tract. The Cmax of obeticholic acid occurs at approximately 1.5 hours after an oral dose and ranges from 28.8-53.7 ng/mL at doses of 5-10mg. The median Tmax for both the conjugates of obeticholic acid is about 10 hours. One product monograph reports a Tmax of 4.5h for both 5 and 10mg doses. The AUC ranged from 236.6-568.1 ng/h/mL with 5mg to 10 mg doses.

About 87% of an orally administered dose is accounted for in the feces. Less than 3% of the dose can be recovered in the urine.

The volume of distribution of obeticholic acid is 618 L.

Clearance information for obeticholic acid is not readily available in the literature.

응용 분야 · 2건

개요Obeticholic acid is a potent and selective farnesoid X receptor agonist that promotes the flow of bile in the liver. The drug was approved by the USFDA for the treatment of the rare chronic liver disease primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with inadequate response to UDCA or as a single agent therapy in adults unable to tolerate UDCA. Obeticholic acid was discovered at the Università de Perugia and developed by Intercept Pharmaceuticals. Obeticholic acid has also been granted orphan drug designation for the treatment of primary sclerosing cholangitis and primary biliary cirrhosis and has received breakthrough therapy designation for the treatment of patients with nonalcohol steatohepatitis (NASH) with liver fibrosis.

용도6-Ethylchenodeoxycholic Acid is a derivative of the bile acid Chenodeoxycholic Acid (C291900). 6-Ethylchenodeoxycholic Acid is a potent activator of the farnesoid X nuclear receptor which reduces liver fat and fibrosis in animal models of fatty liver disease.

추가 설명 · 1건

정의ChEBI: A dihydroxy-5beta-cholanic acid that is chenodeoxycholic acid carrying an additional ethyl substituent at the 6alpha-position. A semi-synthetic bile acid which acts as a farnesoid X receptor agonist and is used for treatme t of primary biliary cholangitis.